GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, ...

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration Co-administration of the RSV and shingles adjuvanted vaccines was ...

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration Co-administration of the RSV and shingles adjuvanted vaccines ...

GSK's Arexvy, Pfizer's Abrysvo and, most recently, Moderna's mResvia. Initially, the CDC said all adults ages 60 and older ...

The Food and Drug Administration approved and granted emergency use authorization on Aug. 22, 2024, for the newest, updated ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

As vaccines against respiratory syncytial virus, or RSV, become available for a second year this fall, health experts are not ...

Arexvy is a brand-name respiratory syncytial ... The Centers for Disease Control and Prevention (CDC) currently recommends women who are pregnant get a different RSV vaccine called RSVpreF ...

The CDC elected not to include one strain ... The FDA approved the first two RSV vaccines — Pfizer’s ABRYSVO and GSK’s AREXVY — in May 2023, marking a major medical breakthrough nearly ...